• RAMYA R Department of Pharmacy Practice, MS Ramaiah University of Applied Sciences, Bengaluru, Karnataka, India.
  • SHARON ANN JOSE Department of Pharmacy Practice, MS Ramaiah University of Applied Sciences, Bengaluru, Karnataka, India.
  • MAMATHA K Department of Pharmacy Practice, MS Ramaiah University of Applied Sciences, Bengaluru, Karnataka, India.
  • SURYA NARAYANA KM Department of Medical Endocrinology, MS Ramaiah Hospitals, Bengaluru, Karnataka, India.


Objective: Polycystic ovarian syndrome (PCOS) is a lifestyle disorder known to cause profound distress in the physical and emotional well-being of the patient that implicates the need for treatment and lifestyle management. Unawareness and ignorance among patients may be a predominant cause of compromised quality of life (QOL) that necessitates education from health-care professionals. The existing study was designed to assess the impact of counseling on QOL in the above patients.

Methods: This hospital-based interventional study was carried out for 6 months. A total of 173 subjects were recruited for the study. The World Health Organization BREF, a validated, reliable tool to assess QOL was administered in two phases of the study, pre-interventional, and post-interventional phase. Awareness regarding disease and lifestyle modification were detailed by a clinical pharmacist to the patients, and its impact was assessed using suitable statistical techniques.

Results: The average age of study participants was 23.9±4.5 years. Decreased QOL was observed in the women affected with PCOS when compared to healthy controls, wherein the psychological domain was the most affected. Post-intervention, a positive impact was reflected as higher scores in all the 4 QOL domains.

Conclusion: Women suffering from PCOS exhibit varied symptoms which affect both physical and psychological health. The key factor in management is to create awareness on the complications of the disease and the lifestyle modification to minimize severity and progression. The study findings reveal that women with PCOS showed an improved QOL post participation in awareness programs imparted by the clinical pharmacists.

Keywords: Polycystic ovarian syndrome, Quality of life, Intervention


1. Asgharnia M, Mirblook F, Ahmad Soltani M. The prevalence of polycystic ovary syndrome (PCOS) in high school students in Rasht in 2009 according to NIH criteria. Int J Fertil Steril 2011;4:156-9.
2. Nehra J, Kaushal J, Singhal SR, Ghalaut VS. Comparision of myo-inositol versus metformin on anthropometric parameters in polycystic ovarian syndrome in women. Int J Pharm Pharm Sci 2017;9:144-8.
3. Deeks AA, Gibson-Helm ME, Teede HJ. Anxiety and depression in polycystic ovary syndrome: A comprehensive investigation. Fertil Steril 2010;93:2421-3.
4. Tabassum K. Ultrasonographic prevalence of polycystic ovarian syndrome in different age groups. Indian J Clin Pract 2014;25:561-4.
5. Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Prevalence of polycystic ovarian syndrome in Indian adolescents. J Pediatr Adolesc Gynecol 2011;24:223-7.
6. Zawadski JK. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Polycystic Ovary Syndrome. Current Issues in Endocrinology and Metabolism. Boston: Blackwell Scientific; 1992. p. 377-84.
7. Lankarani M, Valizadeh N, Heshmat R, Shafaee AR, Amini MR, Larijani MB, et al. Evaluation of dyslipidemia in polycystic ovary syndrome. J Diabetes Metab Disord 2005;4:E11+E11i–E11x.
8. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
9. Ching HL, Burke V, Stuckey BG. Quality of life and psychological morbidity in women with polycystic ovary syndrome: Body mass index, age and the provision of patient information are significant modifiers. Clin Endocrinol (Oxf) 2007;66:373-9.
10. Saxena S, Orley J, WHOQOL Group. Quality of life assessment: The world health organization perspective. Eur Psychiatry 1997;12 Suppl 3:263s-6.
11. Altaf M, Masood QM, Ahmed TZ, Ilyaz M, Basha SA. Health related quality of life assessment using ST. GEORGE’S respiratory questionnaire in chronic obstructive pulmonary disease patients on combined inhaled corticosteroids and bronchodilators. Int J Pharm Pharm Sci 2015;8:445-9.
12. Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med 2001;52:401-19.
13. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
14. Development of the world health organization WHOQOL-BREF quality of life assessment. The WHOQOL group. Psychol Med 1998;28:551-8.
15. The world health organization quality of life assessment (WHOQOL): Development and general psychometric properties. Soc Sci Med 1998;46:1569-85.
16. Shafti V, Shahbazi S. Comparing sexual function and quality of life in polycystic ovary syndrome and healthy women. J Family ReprodHealth 2016;10:92-8.
17. Benetti-Pinto CL, Ferreira SR, Antunes A Jr., Yela DA. The influence of body weight on sexual function and quality of life in women with polycystic ovary syndrome. Arch Gynecol Obstet 2015;291:451-5.
18. Elsenbruch S, Hahn S, Kowalsky D, Offner AH, Schedlowski M, Mann K, et al. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:5801-7.
19. Chen X, Yang D, Mo Y, Li L, Chen Y, Huang Y, et al. Prevalence of polycystic ovary syndrome in unselected women from Southern China. Eur J Obstet Gynecol Reprod Biol 2008;139:59-64.
20. Kumarapeli V, Seneviratne Rde A, Wijeyaratne C. Health-related quality of life and psychological distress in polycystic ovary syndrome: A hidden facet in South Asian women. BJOG 2011;118:319-28.
21. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Futterweit W, et al. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An androgen excess society guideline. J Clin Endocrinol Metab 2006;91:4237-45.
22. Emans S, Laufer M, Goldstein D. Pediatric and Adolescent Gynecology. 5th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2005. p. 287- 96, 304-23.
23. Laitinen J, Taponen S, Martikainen H, Pouta A, Millwood I, Hartikainen AL, et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int J Obes Relat Metab Disord 2003;27:710-5.
24. Melmed S. Williams’s Textbook of Endocrinology. Philadelphia, PA: Elsevier Health Sciences; 2016.
25. Cupisti S, Kajaia N, Dittrich R, Duezenli H, W Beckmann M, Mueller A, et al. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. Eur J Endocrinol 2008;158:711-9.
26. Vrbikova J, Hainer V. Obesity and polycystic ovary syndrome. Obes Facts 2009;2:26-35.
27. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006;91:492-7.
28. Kiddy DS, Sharp PS, White DM, Scanlon MF, Mason HD, Bray CS, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: An analysis of 263 consecutive cases. Clin Endocrinol (Oxf) 1990;32:213-20.
29. Liou TH, Yang JH, Hsieh CH, Lee CY, Hsu CS, Hsu MI, et al. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women. Fertil Steril 2009;92:1960-5.
30. Tremblay MS, Colley RC, Saunders TJ, Healy GN, Owen N. Physiological and health implications of a sedentary lifestyle. Appl Physiol Nutr Metab 2010;35:725-40.
31. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-91.
32. Utriainen P, Laakso S, Liimatta J, Jääskeläinen J, Voutilainen R. Premature adrenarche – a common condition with variable presentation. Horm Res Paediatr 2015;83:221-31.
33. Voutilainen R, Jääskeläinen J. Premature adrenarche: Etiology, clinical findings, and consequences. J Steroid Biochem Mol Biol 2015;145:226-36.
34. Ibáñez L, Potau N, Francois I, de Zegher F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: Relation to reduced fetal growth. J Clin Endocrinol Metab 1998;83:3558-62.
35. Potau N, Ibañez L, Riqué S, Carrascosa A. Pubertal changes in insulin secretion and peripheral insulin sensitivity. Horm Res 1997;48:219-26.
36. Singla R, Gupta Y, Khemani M, Aggarwal S. Thyroid disorders and polycystic ovary syndrome: An emerging relationship. Indian J Endocrinol Metab 2015;19:25-9.
37. Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuangsoongnoen N, Rojanasakul A, et al. Prevalence of Type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynaecol Obstet 2001;75:177-84.
38. Gambineri A, Pelusi C, Manicardi E, Vicennati V, Cacciari M, Morselli-Labate AM, et al. Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome: Phenotype and associated factors. Diabetes 2004;53:2353-8.
39. Hahn S, Janssen OE, Tan S, Pleger K, Mann K, Schedlowski M, et al. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol 2005;153:853-60.
40. McCook JG, Reame NE, Thatcher SS. Health-related quality of life issues in women with polycystic ovary syndrome. J Obstet Gynecol Neonatal Nurs 2005;34:12-20.
47 Views | 0 Downloads
How to Cite
RAMYA R, SHARON ANN JOSE, MAMATHA K, and SURYA NARAYANA KM. “QUALITY OF LIFE IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME: REQUISITE OF CLINICAL PHARMACIST INTERVENTION”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 12, no. 11, Sept. 2019, pp. 100-5, doi:10.22159/ajpcr.2019.v12i11.34426.
Original Article(s)